Page 86 - 81_04

Tuberculosis is not an illness of the past
44. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X.
Global tuberculosis drug development pipeline: the
need and the reality. Lancet. 2010; 375: 2100-9.
45. Sacksteder KA, Protopopova M, Barry CE, Andries K,
Nacy CA. Discovery and development of SQ109: a
new antitubercular drug with a novel mechanism of
action. Future Microbiol 2012; 7: 823-37.
46. Bogatcheva E, Hanrahan C, Nikonenko B, et al.
Identification of SQ609 as a lead compound from a
library of dipiperidines. Bioorg Med Chem Lett 2011;
21: 5353-57.
47. Alffenaar JWC, van der Laan T, Simons S, et al.
Susceptibility of Clinical Mycobacterium tuberculosis
isolates to a potentially less toxic derivate of linezolid,
PNU-100480. Antimicrob Agents Chemother 2011;
55: 1287-89.
48. Phase 2a EBA Trial of AZD5847. ClinicalTrials.gov
Identifier: NCT01516203.
49. Ananthan S, Faaleolea ER, Goldman RC, et al. High-
throughput screening for inhibitors of Mycobacterium
tuberculosis H37Rv. Tuberculosis 2009; 89: 334-53.
50. Dye C. Tuberculosis 2000-2010: control, but not
elimination. Int J Tuberc Lung Dis 2000; 4: S146–
S152.
51. a) Elliott AM, Berning SE, Iseman MD, Peloquin CA.
Failure of drug penetration and acquisition of drug
resistance in chronic tuberculous empyema. Tuber
Lung Dis 1995; 76: 463–467. b) Wayne LG.
Dormancy of Mycobacterium tuberculosis and latency
of disease. Eur J Clin Microbiol Infect Dis 1994; 13:
908-14.
52. Gillespie SH. Evolution of Drug Resistance in
Mycobacterium tuberculosis: Clinical and Molecular
Perspective. Antimicrob. Agents Chemother 2002; 46:
267-74.
53. a) Dinakaran M, Senthilkumar P, Yogeeswari P, et al.
Novel ofloxacin derivatives: synthesis,
antimycobacterial and toxicological evaluation.
Bioorg Med Chem Lett 2008; 18, 1229-36. b) Chopra
S, Matsuyama K, Tran T, et al. Evaluation of gyrase B
as a drug target in Mycobacterium tuberculosis. J
Antimicrob Chemother 2012, 67: 415-21. c) Shirude
PS, Madhavapeddi P, Tucker JA, et al.
Aminopyrazinamides: novel and specific GyrB
inhibitors that kill replicating and nonreplicating
Mycobacterium tuberculosis. ACS Chem Biol 2013;
8: 519-23. d) Karkare S, Chung TT, Collin F, et al.
The naphthoquinone diospyrin is an inhibitor of DNA
gyrase with a novel mechanism of action. J Biol Chem
2013; 288: 5149-56.
54. McKee EE, Ferguson M, Bentley AT, Marks TA.
Inhibition of mammalian mitochondrial protein
synthesis by oxazolidinones. Antimicrob Agents
Chemother 2006; 50: 2042-49.
55. Ver por ejemplo: a) Makarov V, Manina G, Mikusova
K, et al. Benzothiazinones kill Mycobacterium
tuberculosis by blocking arabinan synthesis. Science
@Real Academia Nacional de Farmacia. Spain
2009; 324: 801-4. b) Pasca MR, Degiacomi G, Ribeiro
AL, et al. Clinical isolates of Mycobacterium
tuberculosis in four European hospitals are uniformly
susceptible to benzothiazinones. Antimicrob Agents
Chemother 2010; 54: 1616-18.
56. a) Boechat N, Ferreira VF, Ferreira SB, De Lourdes
GFM, et al. Novel 1,2,3-triazole derivatives for use
against Mycobacterium tuberculosis H37Rv (ATCC
27294) strain. J Med Chem 2011; 54, 5988-99. b)
Lamichhane G. Novel targets in M. tuberculosis:
search for new drugs, Trends Mol Med 2011, 17: 25-
33.
57. Ver por ejemplo: a) Sullivan TJ, Truglio JJ, Boyne
ME, et al. High affinity InhA inhibitors with activity
against drug-resistant strains of Mycobacterium
tuberculosis. ACS Chem Biol 2006; 1: 43-53. b)
Vilcheze C, Baughn AD, Tufariello J, et al. Novel
inhibitors of InhA efficiently kill Mycobacterium
tuberculosis under aerobic and anaerobic conditions.
Antimicrob Agents Chemother 2011; 55: 3889-98. c)
Kinjo T, Koseki Y, Kobayashi M, et al. Identification
of compounds with potential antibacterial activity
against Mycobacterium through structure-based drug
screening. J Chem Inf Model 2013; 53: 1200-12.
58. Parikh SL, Xiao G, Tonge PJ. Inhibition of InhA, the
enoyl reductase from Mycobacterium tuberculosis, by
triclosan and isoniazid. Biochemistry 2000; 39: 7645-
50.
59. Wang F, Langley R, Gulten G, et al. Mechanism of
thioamide drug action against tuberculosis and
leprosy. J Exp Med 2007; 204: 73-8.
60. a) He X, Alian A, Stroud R, Ortiz de Montellano PR.
Pyrrolidine carboxamides as a novel class of inhibitors
of enoyl acyl carrier protein reductase from
Mycobacterium tuberculosis. J Med Chem 2006; 49:
6308-23. b) Ballell L, Castro J, Fernandez R, et al.
(Pyrazol-3-yl)-1,3,4-thiadiazole-2-amine and (pyrazol-
3-yl)-1,3,4-thiazole-2-amine compounds. World
Intellectual Property Organization 2010;
WO2010118852 A1.
61. a) Hartkoorn RC, Sala C, Neres J, et al. EMBO Mol
Med 2012; 4: 1032-42. b) Avendaño C. Hacia un
nuevo fármaco antituberculoso. Anales RANF? 2012;
78: 288-97. c) Perryman AL, Yu W, Wang X, et al. A
Virtual Screen Discovers Novel, Fragment-Sized
Inhibitors of Mycobacterium tuberculosis InhA. J
Chem Inf Model 2015; 55: 645-59.
62. Hartkoorn RC, Pojer F, Read JA, Gingell H, et al.
Pyridomycin bridges the NADH- and substrate-
binding pockets of the enoyl reductase InhA. Nature
Chem Biol 2014; 10: 96-99.
63. Ver: Altmann K-H, Horlacher O, Hartkoorn R, S
(inventors). Pyridomycin based compounds exhibiting
an antitubercular activity. Patente WO2014040709
A1, 20 Marzo de 2014.
64. a) Wolff KA, Nguyen L. Strategies for potentiation of
ethionamide and folate antagonists against
355